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Mariana Murea1, Shahriar Moossavi1, Liliana Garneata2 and Kamyar Kalantar-Zadeh3
1Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Winston-Salem, North Carolina,
USA; 2Department of Internal Medicine, Section on Nephrology, “Dr Carol Davila” University Hospital of Nephrology,
Bucharest, Romania; and 3Department of Internal Medicine, Section on Nephrology, University of California Irvine School of
Medicine, Orange, California, USAThe prescription of hemodialysis (HD) in patients with incident end-stage kidney disease (ESKD) is
fundamentally empirical. The abrupt transition from nondialysis chronic kidney disease (CKD) to thrice-
weekly in-center HD of much the same dialysis intensity as in those with prevalent ESKD under-
appreciates the progressive nature of kidney disease whereby the decline in renal function has been
gradual and ongoing—including at the time of HD initiation. Adjuvant pharmacologic treatment (i.e., di-
uretics, acid buffers, potassium binders), coupled with residual kidney function (RKF), can complement an
initial HD regimen of lower intensity. Barriers to less intensive HD in incident ESKD include risk of inad-
equate clearance of uremic toxins due to variable and unexpected loss of RKF, lack of patient adherence to
assessments of RKF or adjustment of HD intensity, increased burden for all stakeholders in the dialysis
units, and negative financial repercussions. A stepped dialysis regimen with scheduled transition from
time-delineated twice-weekly HD to thrice-weekly HD could represent an effective and safe strategy to
standardize incremental HD in patients with CKD transitioning to early-stage ESKD. Patients’ adherence
and survival as well as other clinical outcomes should be rigorously evaluated in clinical trials before large-
scale implementation of different incremental schedules of HD. This review discusses potential benefits of
and barriers to alternative dialysis regimens in patients with incident ESKD, with emphasis on twice-
weekly HD with pharmacologic therapy, and summarizes in-progress clinical trials of incremental HD
schedules.
Kidney Int Rep (2020) 5, 135–148; https://doi.org/10.1016/j.ekir.2019.11.014
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).M ore than half a century from the construct andintroduction of hemodialysis (HD) therapy as
treatment for end-stage kidney disease (ESKD), the
optimal prescription (i.e., frequency, duration, and
dose) of HD treatment is unsettled. In most developed
countries, the vast majority of patients with ESKD
receiving HD are treated with a conventional regimen
of thrice-weekly in-center HD of full intensity (i.e.,
to achieve a minimum dialysis single pool Kt/Vurea
[spKt/Vurea] $1.2 and urea reduction ratio
[URR] $65%), whether the patient is new to dialysis
treatment (incident) or has been undergoing dialysis
therapy for a while (prevalent). Unlike the science
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International Reports (2020) 5, 135–148kidney function, rigorous trials of standardized HD
prescription in patients with incident ESKD have not
been conducted, especially for those who still make
considerable amounts of urine.1,2 Furthermore, health
care resources have a bearing on practice patterns. In
economically disenfranchised countries (e.g., Asia, Af-
rica, and Latin America), incremental in-center HD
(e.g., twice- or even once-weekly HD) is prescribed to
25% to 50% of the HD population, being as common
as near 100% of patients with ESKD in some regions
of India.35 Therefore, less intensive schedules of HD
can be afforded in ESKD, owing to persistent low levels
of kidney function; this kidney function, not uncom-
monly associated with 1 to 2 L of urine output per
day, has been dubbed the residual kidney function
(RKF).
Incremental HD denotes gradual adjustments in the
dialysis prescription (i.e., frequency, treatment time,
blood flow, dialysate flow, etc.), guided by changes in
RKF. Under this umbrella concept, several regimens of
HD have been probed: twice-weekly HD with later
conversion to thrice-weekly HD dictated by changes in135
REVIEW M Murea et al.: Hemodialysis in Early-Stage ESKDRKF or changes in clinical status in the absence of as-
sessments of RKF; once-weekly HD with low-protein
diet followed by later changes to more frequent HD
schedules; or thrice-weekly HD with short treatment
sessions (<4 hours per session) followed by increase in
treatment length ($4 hours per session).6 Although
protein-restricted diets with nitrogen-free ketoacid
analogues have been reported as effective and safe
means to reduce the rate of kidney function decline and
delay dialysis initiation,7,8 the application of these di-
etary modifications in patients receiving HD remains to
be investigated. Nutrition-related indexes are recog-
nized as strong prognostic factors for all-cause and
cardiovascular morbidity and mortality in patients on
chronic HD.9 The rise in prevalence rates of protein-
energy wasting according to HD duration ought to be
acknowledged,10 yet the optimal level and composition
of protein intake in patients with incident ESKD and its
effects on RKF, cardiovascular outcomes, and survival
have not been studied. Thus, until research brings
more clarity, a dietary approach for incremental HD
should be regarded with caution.
Irrespective of the incremental HD schedule used at
dialysis initiation, regular assessment of endogenous
renal function is an integral part in its prescription.
Although a regimen of incremental HD consisting of
adjustment in treatment length rather than treatment
frequency may have least have an impact on the cur-
rent infrastructure of the dialysis units, incremental
dialysis requires a very high level of commitment from
the nephrologist, the dialysis unit staff, and foremost
the patient. Shorter HD treatments will yield subtarget
dialysis clearance metrics, which, in the absence of
concomitant renal clearance measurements, will be
challenged as inadequate dialysis in the United States,
within the mandatory federal reporting of urea clear-
ance metrics for patients undergoing thrice-weekly
HD. To this date, the safety and efficacy of 1 regimen
of incremental HD over another is not known, as these
regimens have not been directly compared. In this
article, we focus our debate on the prescription of
twice-weekly versus conventional thrice-weekly in-
center HD and propose a regimen of stepped HD pre-
scription consisting of time-delineated twice-weekly
in-center HD with adjuvant pharmacologic therapy in
patients with incident ESKD.
The Pervasive Unknowns of HD Dose
A one-size-fits-all HD therapy approach is in discord
with one of the tenets of medical practice: treatment of
disease based on illness severity. The target HD treat-
ment dose applied in conventional HD prescription was
derived from clinical trials that involved solely prev-
alent HD patients with dialysis vintage >2 years and136very low to no RKF1,2; this was then extrapolated as an
optimal dialysis dose to all dialysis patients, including
those with incident ESKD and appreciable RKF. Barring
the endeavor of recent Frequent Hemodialysis Network
trials that compared more-frequent HD with conven-
tional HD, no randomized controlled trial has examined
whether less frequent HD treatments (or other sched-
ules of incremental HD) would be practicable, benefi-
cial, or harmful in patients with incident ESKD.11,12
As such, in the current state of clinical practice, HD
prescription for patients with ESKD is stereotypical and
oblivious of RKF, most commonly consisting of thrice-
weekly HD to specific targets of dialysis spKt/Vurea and
URR.
The schedule of HD therapy has, however, trans-
formed over years. At its inception, nearly 7 decades
ago, HD was performed as 24-hour weekly treatments;
the practice gradually changed to 12-hour twice-
weekly sessions, 8- to 12-hour thrice-weekly sessions,
and then finally to short 3- to 4-hour thrice-weekly
schedules, changes largely made possible by techno-
logical advances in dialysis engineering and shaped by
logistical operations.13,14 In early 1970s, Babb and
Milutinovic et al. called attention to residual glomer-
ular filtration rate, affirming that “it is [now] apparent
that it is necessary to consider the effect of RKF in
prescribing a treatment protocol for a given patient”;
their recommendation did not permeate clinical prac-
tice.15,16 Alongside, the prescription of HD progressed
from bedside assessment of uremic symptoms (e.g.,
reversal of uremic coma) to serum-based HD dose
quantification (i.e., time-averaged concentration of
blood urea nitrogen [BUN], Kt/Vurea, URR). The
generalized acquiescence to a conventional dialysis
schedule and target and minimum urea clearance met-
rics in patients treated with HD is a composite result of
two clinical trials (the National Cooperative Dialysis
Study [NCDS] and the Effect of Dialysis Dose and
Membrane Flux in Maintenance Hemodialysis [HEMO]
study),1,2 bolstered by clinical practice guidelines,17,18
intertwined with government regulations.19 In the
NCDS, patients with prevalent ESKD and residual
creatinine clearance #3 ml/min on thrice-weekly HD
were randomized to test the effect of achieving higher
and lower BUN concentrations. The trial, based on 151
patients, showed that the groups with time-averaged
BUN concentrations of approximately 50 mg/dl fared
better (i.e., longer time to first hospitalization) than
those with time-averaged BUN concentrations of
approximately 80 mg/dl.1 Gotch and Sargent converted
time-averaged BUN as a function of spKt/Vurea, and
their re-analysis of the NCDS data showed that patients
with spKt/Vurea <0.8 had a high relative probability of
failure (composite endpoint of death, hospitalization,Kidney International Reports (2020) 5, 135–148
M Murea et al.: Hemodialysis in Early-Stage ESKD REVIEWand de novo uremic symptoms) irrespective of BUN or
normalized protein catabolic rate.20 These results set
the first benchmark for a minimum dialysis dose de-
livery at spKt/Vurea $1.0; this target was set 25%
higher than the so-called spKt/Vurea break point iden-
tified in the NCDS trial. The HEMO study used the
construct Kt/Vurea as the principal measure of the dose
of dialysis, and showed that an increase in spKt/Vurea
from approximately 1.4 to 1.7 on a thrice-weekly HD
regimen, in patients with prevalent ESKD and residual
urea clearance <1.5 ml/min per 35 L of urea, afforded
no clinical outcome benefit.2
In the aftermath of the aforementioned landmark
trials, the Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines recommended a target spKt/Vurea of
1.4 per HD session for patients treated thrice weekly,
with a minimum delivered spKt/Vurea of 1.2.
17 The
upward drift in the target spKt/Vurea from 1.0 to 1.4,
which occurred without the support of a clinical trial,
is reinforced in the United States by the regulatory
bodies of the Centers for Medicare and Medicaid Ser-
vices (CMS). Intricacies of the implicit social contract
between the population of the United States and its
government regarding treatment of ESKD put aside,
many positive aspects are to be highlighted, such as
government-financed entitlement to HD care and cost
containment.19 Although it may seem that part of the
reason that countries other than the Unites States are
successful at performing and studying less frequent HD
is lax federal oversight on dialysis metrics, the report-
ing of dialysis dose adequacy in the United States is not
required by the CMS for patients undergoing HD at
schedules other than thrice weekly. In fact, should
adequate research prove the effectiveness of incremen-
tal HD, a change in CMS rules could force adaptation of
timely urine collections and measurement of RKF in
clinical practice. Meanwhile, the financial drawbacks to
dialysis units’ stakeholders brought about by less
frequent HD schedules are curbing the acceptance of
performing and studying less frequent HD.
Unlike treatment of ESKD with peritoneal dialysis
(PD), the ease of achieving adequate solute clearance
with HD allows the treating physicians to disregard
RKF quantification. Because of the inherent nature of
less efficient solute clearance with PD, patients started
on renal replacement therapy with this modality tend
to have higher levels of RKF at dialysis initiation than
those started on HD. The reliance on RKF to achieve
adequate solute clearance in patients initiated on PD
compels providers to obtain periodic measurements of
intrinsic kidney function. The prescription of PD is
subsequently titrated based on changes in RKF; for this
reason, RKF has been referred to as the heart of PD.21 In
contrast, the inclusion of RKF in HD prescription hasKidney International Reports (2020) 5, 135–148been left up to the discretion of the nephrologist, with
scant guidance on how to perform incremental HD
(discussed below). Although we acknowledge the effi-
ciency, quality, and current acceptance of a stream-
lined, thrice-weekly HD approach—independent of
RKF—for medical professionals, recasting ESKD under
a progression model, with its own stages, may compel
more recognition to a regressive kidney function in
patients who transition from predialysis chronic kid-
ney disease (CKD) to early-stage ESKD.
Early-Stage ESKD
Residual Kidney Function
It has been estimated that nearly half of the patients
with CKD who progress to ESKD and require initiation
of renal replacement therapy have an appreciable
amount of RKF present at the time of dialysis.22,23
Although the ESKD designation lends the inference
of comparable kidney function deficit in those afflicted,
we argue that the final stage of kidney disease can be
broadly divided, for clinical purposes, into 2 substages:
early-stage ESKD in the initial period of HD therapy
(present in up to 50% of incident patients), and late-
stage ESKD (prevalent patients) demarcated by a
shortfall in RKF. Just as the progression of kidney
disease tracks heterogeneous patterns in adult patients
with CKD,24 kidney function regression from pre-
dialysis CKD to ESKD may follow several paths, and
perhaps not all patients reach late-stage ESKD
(Figure 1). Our speculation of transition patterns from
CKD to different stages of ESKD needs to be verified
with clinical data obtained in prospective studies.
In the year 2015, national statistics from the United
States Renal Data System (USRDS) reported a mean
estimated glomerular filtration rate (eGFR) at dialysis
initiation of 9.8 ml/min per 1.73 m2; 39% of all patients
with incident ESKD had an eGFR at $10 ml/min per
1.73 m2 at dialysis initiation.25,26 Based on a USRDS
registry cohort of 971,481 patients who initiated dial-
ysis between 1995 and 2012, Li et al. showed that the
mean eGFR at dialysis initiation rose monotonically
from 7.7 in 1995 to 11.1 in 2009 and 10.9 ml/min per
1.73 m2 in 2012; >90% of all incident dialysis patients
had an eGFR of $5 ml/min per 1.73 m2 at dialysis
initiation.22 As a result, a large proportion of patients
with incident ESKD have substantial RKF that may
confer, at least provisionally, partial solute clearance
and volume control. Initiation of HD with a less
frequent regimen is conceivably a suitable dialysis
schedule in patients with early-stage ESKD and clini-
cally evident RKF.27 Chin et al. estimated the feasibility
of twice-weekly HD for patients in the United States
with incident ESKD. The authors examined the pro-
portion of patients that could have started maintenance137
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Figure 1. Hypothetical plots of different patterns of progression from chronic kidney disease (CKD) to end-stage kidney disease (ESKD): gradual
transition from CKD to late-stage ESKD, passing through early-stage ESKD; possible candidate for incremental dialysis (blue-line trajectory);
intermediate transition from CKD to early-stage ESKD with prolonged dwell in early-stage ESKD; ideal candidate for incremental dialysis (green-
line trajectory); and abrupt transition from CKD to late-stage ESKD; likely not a candidate for incremental dialysis (red-line trajectory).
REVIEW M Murea et al.: Hemodialysis in Early-Stage ESKDHD with a twice-weekly schedule based on 4 criteria:
weekly urea clearance (i.e., standard Kt/Vurea [stdKt/
Vurea]); interdialytic weight gain; intradialytic blood
pressure; and intradialytic symptoms such as nausea
and vomiting. On the basis of total stdKt/Vurea (deliv-
ered by dialysis and RKF), ultrafiltration rate, and
blood pressure stability, the authors calculated that
approximately one-third of incident hemodialysis pa-
tients (i.e., 219 of 646) would qualify for an initial
schedule of twice-weekly HD.23
Adjuvant Pharmacologic Therapy
The key to providing less frequent HD safely in pa-
tients with incident, early-stage ESKD is patient selec-
tion, with the core criterion revolving around the level
of RKF. Residual renal solute clearance is calculated as
the amount of solute in interdialytic urine collection
divided by the average of plasma solute concentration
at the beginning and end of the collection period. A
detailed discussion about RKF is beyond the scope of
this article, and readers are referred to recent review
articles for this topic.28,29 When present, RKF provides
fluid and salt removal, phosphorus excretion, endoge-
nous vitamin D and erythropoietin production, and
greater clearance of protein-bound solutes and middle
molecules.3033 In addition, RKF provides continuous
solute clearance either by filtration or by tubular
secretion, which is not provided by HD.34 In a recent
study, plasma concentrations of secreted solutes (hip-
purate, phenylacetylglutamine, indoxyl sulfate, and p-
cresol sulfate) were as well controlled in patients with
mean (standard deviation) residual renal urea clearance
(Kru) 2.8 (1.5) ml/min on twice-weekly HD as in anuric
patients on thrice-weekly HD.35 Remarkably, a previ-
ously considered clinically negligible level of RKF (i.e.,
urinary urea clearance#1.5ml/min) may in fact make a
significant clinical difference. Toth-Manikowski et al.138analyzed serum levels of uremic solutes and clinical
outcomes in 1280 participants from the HEMO study,
34% of whom had average residual kidney urea clear-
ance of 0.7  0.4ml/min per 35 L total body water, and
66% had no RKF.36 Among those with RKF, 7 of 8
measured non-urea solutes were in lower concentrations
compared with levels in patients without RKF, irre-
spective of the HD prescription; the difference ranged
from 24% to 3.7% lower (P < 0.05). Having RKF at
baseline was associated with a trend toward a 14% lower
risk of cardiovascular events; and a maintained RKF at 1
year of follow-up was associated with a 19% lower risk
of death, 25% lower risk of cardiac death, and 16%
lower risk of first cardiovascular event.36 Therefore,
even at very low levels, RKF is consequential.
A tendency in clinical practice is to decrease the
dose of or to discontinue the medications that were
heavily relied upon in advanced CKD stages: diuretics,
potassium-binding agents, and acid buffers. Should a
regimen of twice-weekly HD be used at dialysis initi-
ation, these medications can be used to augment and
supplement RKF, and to bridge transition from less
frequent to thrice-weekly or more frequent HD. When
the issue of diuretic prescription was analyzed by Chin
et al., the findings suggested that an additional 25% of
patients with incident ESKD could have been managed
by twice-weekly HD if they had received diuretic
therapy.37 In contrast, diuretics are much more
commonly used in patients who are treated with PD at
dialysis initiation, for whom an escalating regimen of
PD frequency and intensity is commonly pre-
scribed.38,39 In 1 trial, 61 patients new to dialysis were
randomly assigned to either loop diuretic medication
furosemide 250 mg every day or no furosemide at the
time of PD training.40 The results were expressed on an
intention-to-treat basis, and showed that long-term
furosemide produced a significant increase in urineKidney International Reports (2020) 5, 135–148
M Murea et al.: Hemodialysis in Early-Stage ESKD REVIEWvolume over 12 months of follow-up (þ176 ml/24 h in
the diuretic group vs. 200 ml/24 h in the control
group at 6 months and þ48.8 vs. 305 ml/24 h,
respectively, at 1 year; P < 0.05) and resulted in
clinically significant improvement in fluid balance.40 It
can be advanced that in patients with progressive CKD
and incident ESKD receiving HD, diuretics can
ameliorate weight gains between dialysis sessions and
lessen unsafe ultrafiltration rates while patients are
receiving a time-limited regimen of lower-frequency
HD.
Safer medications can now be used to maintain
control of serum potassium in patients treated with less
frequent HD. Two newer potassium binders, patiromer
calcium and sodium zirconium cyclosilicate, have been
safely used for potassium imbalance treatment in pa-
tients with CKD and heart failure while on therapy
with reninangiotensinaldosterone system (RAAS)
inhibitors. Patiromer calcium has been shown to
effectively reduce serum potassium levels,41 to main-
tain long-term normokalemia,42,43 and to prevent
hyperkalemia.4446 In 1 trial using zirconium, a dose-
dependent increase in the incidence of edema was
observed.47 Based on these data, it can be anticipated
that the use of patiromer can overcome the risk of
hyperkalemia and enhance the tolerability of RAAS
inhibitor in patients with incident ESKD treated with
less frequent HD regimens.
Timed Urine Collection
A set of clinical criteria to aid in the identification of
patients with ESKD suitable for less frequent HD has
been proposed, with the core requirement being the
presence of urine output >600 ml/d or Kru >3.0 ml/
min, and suggest that an incremental transition from
twice- to thrice-weekly would be necessary if urine
output drops to <500 ml/d or Kru drops to <2.0 ml/
min.48,49 Other clinical factors have been considered,
such as absence of severe hyperkalemia and hyper-
phosphatemia, absence of severe cardiovascular and
pulmonary disease, lack of profound anemia, and fluid
retention <2.5 kg between 2 consecutive HD treat-
ments done 3 to 4 days apart.50,51
In the opinion of the KDOQI Work Group, less
frequent HD could be practiced as long as Kru remains
>2.0 ml/min, provided that Kru is measured periodi-
cally. Because RKF declines over time and large varia-
tions in change in RKF exist, the Group set a practical
cut-off Kru of 2.0 ml/min per 1.73 m2, below which Kru
should be ignored.17 As schedules of less frequent HD
rely on objective quantification of RKF, baseline and
follow-up interdialytic urine collections (when the
collection period begins and ends within an inter-
dialysis interval) at intervals of 1 to 3 months stand asKidney International Reports (2020) 5, 135–148prerequisites in patient identification and modeling of
HD prescription. This criterion is a daunting task,
given uncertainties in obtaining appropriate urine
collections. Regular urine collection between 2 dialysis
sessions and its coordination are cumbersome, both for
the patient and for the staff. In addition, under- or
overcollection of urine is common in practice, and no
methods can reliably assess the accuracy of timed urine
collection, especially among patients in whom native
clearance data may be confounded by the added
clearance from the HD therapy.52
Studies that looked at the frequency of timed urine
collection to assess Kru showed a low rate in attaining
these tests, even at dialysis units that more commonly
perform less frequent HD. In a study by Mathew et al.,
the median prevalence of urine collection during the
first 91 days of dialysis was 33%, 42%, and 56%
among dialysis facilities that had a prevalence of in-
cremental HD of 0%, >0% to 3%, and >3%, respec-
tively; the trend for higher prevalence of urine
collection with rising facility prevalence of incremental
HD was statistically significant (P trend <0.001).53 The
regularity of timed urine collection was estimated in a
cohort of 23 patients with incident ESKD, initiated on a
regimen of twice-weekly HD and later switched to
thrice-weekly HD; timed urine collection at dialysis
initiation was identified only in 12 patients, with
recorded mean urine output of 1128 (233) ml/d; at
follow-up, only 2 patients had completed a 24-hour
urine collection during the course of treatment with
twice-weekly HD.54
Methods to assess RKF in patients on dialysis
without reliance on urine collections have been
explored. Several investigators developed mathematical
formulae for cross-sectional estimation of RKF in pa-
tients on chronic HD.5557 The equations, based on
serum biomarkers (urea, creatinine, b-trace protein, b2-
microglobulin, cystatin C), were compared against
measured urinary clearance of urea and creatinine
collected as part of clinical care. In those studies, the
precision in estimating RKF was significantly better for
b-trace protein- and b2-microglobulinbased equa-
tions, whereas the accuracy was significantly greater
for b-trace protein, b2-microglobulin, and cystatin
Cbased equations. Overall, RKF estimation equations
had low sensitivity but high specificity to classify pa-
tients above or below Kru of 2 ml/min. However, bias
between measured and estimated RKF was approxi-
mately w0.5 ml/min with relatively wide limits of
agreement, suggesting that b-trace protein and b2-
microglobulinbased estimating equations may not
be accurate enough to replace timed urine collections.
Furthermore, the equations underestimated the change
in kidney function over time. Other limitations of the139
REVIEW M Murea et al.: Hemodialysis in Early-Stage ESKDestimating equations include lack of validation against
inulin clearance, and lack of laboratory standards for b-
trace protein and b2-microglobulin measurement.29,58
To date, the goal of using equations that estimate
RKF from serum markers without urine collection in
patients on dialysis remains unmet.
Prescribing Less Frequent HD
The metric of stdKt/Vurea was advanced to normalize
the HD prescription by the frequency of dialysis
treatments, constructed around the target of dialysis
spKt/Vurea in patients with prevalent ESKD on thrice-
weekly HD.59,60 The 2015 KDOQI opinion-based
guidelines for HD adequacy recommend a target
stdKt/Vurea of 2.3 across all schedules of HD, with a
minimum delivered dose of 2.1; for less frequent HD
schedules, a method of total stdKt/Vurea calculation that
includes the combined contributions of ultrafiltration
and RKF was proposed.17
In the United States, when less frequent HD is pre-
scribed, patients are generally started on twice-weekly
HD, but some clinicians in other countries initiate
dialysis with a regimen of once-weekly HD, including
in combination with a low-protein diet on nondialysis
days.61 A Kru of 2 ml/min confers a weekly renal urea
clearance of 0.50 for a volume of distribution of urea of
40 L, 0.57 for a volume of distribution of urea of 35 L,
and 0.67 for a volume of distribution of urea of 30 L.
Using the urea kinetic modeling according to different
dialysis modalities developed by Gotch, residual renal
clearance at dialysis initiation can supplement an initial
HD prescription of lower frequency but higher dose
(i.e., twice-weekly HD with dialysis spKt/Vurea $1.60).
In this scenario, twice-weekly HD prescription would
involve longer-than-usual treatment times (i.e.,
240270 minutes vs. 200230 minutes).62 Less
frequent HD is maintained until Kru is <2.0 ml/min;
stdKt/Vurea cannot be maintained $2.1 when
combining dialysis Kt/Vurea and Kru; and/or clinical
manifestations and/or laboratory findings suggest
suboptimal dialysis. Practiced in this manner, the
success of incremental HD depends on the accom-
plishment of accurate, frequent and timely measure-
ments of RKF with interdialytic urine collection.
Keeping pace with regular, timed urine collection tests
may not be a tenable task in real life or busy clinical
practice, and especially not until large dialysis orga-
nizations operationalize the process.
It is important to mention here that there have been
no clinical trials conducted to assess the association of
achieved stdKt/Vurea with clinical outcomes in patients
undergoing HD, regardless of ESKD stage (incident or
prevalent) or dialysis frequency. In 1 retrospective
study, Rivara et al. evaluated the predictive value of140stdKt/Vurea for clinical outcomes.
63 In their study, us-
ing nationally representative data from a large dialysis
provider in the United States, dialysis stdKt/Vurea $2.3
was associated with a modestly lower risk for all-cause
mortality compared with stdKt/Vurea 2.1 to <2.3
(adjusted hazard ratio ¼ 0.97, 95% confidence interval
[CI] ¼ 0.94–0.99). In individuals with available data on
RKF and models adjusting for kidney stdKt/Vurea,
dialysis, stdKt/Vurea $2.3 was not associated with
decreased risk of mortality or hospitalization compared
with the referent category.63
Among the main challenges related to the prescrip-
tion of incremental HD are an arbitrary use of infre-
quent regimens and the lack of clear (and
undemanding) standards for incorporating RKF in the
assessment of HD dose. There is a large variability in
the practice of incremental HD between countries,
across practices in the same country, and between
providers at the same practice. In a nationally repre-
sentative sample of 434 incremental and 50,162 con-
ventional HD patients from 1737 dialysis facilities
across the United States, 74% (1293) of the dialysis
facilities did not have any patients treated with incre-
mental HD between January 2007 and December 2011;
17% (288) of the facilities had between 0% and 3% of
the incident HD patients treated with incremental HD,
and 9% (156) of the facilities had>3% of their incident
population treated with incremental HD.53 Not sur-
prisingly, patients prescribed twice-weekly HD had
better baseline Kru and higher urine volume than those
prescribed conventional thrice-weekly HD; no signifi-
cant difference was noted in age and comorbidities
between patients treated with incremental HD and
those treated with a conventional HD regimen.64
The complexity of prescribing less frequent HD is
augmented by the fact that the rate of RKF decline is
unpredictable and exhibits large variations across pa-
tients, and clinical events can affect its trajectory
(Figure 1). Patients may have slow deterioration of
kidney function, moving from predialysis CKD to
phases of early-stage ESKD when requiring HD initia-
tion; these patients are good candidates for prescription
of incremental HD (Figure 1, green-line trajectory).
However, some patients have direct or rapid change in
kidney function from predialysis CKD to late-stage
CKD, and these patients would not be considered
good candidates for prescription of incremental HD
(Figure 1, red- and blue-line trajectories). Factors
associated with faster decline in RKF are female sex,
nonwhite race, diabetes, congestive heart failure, un-
controlled hypertension, proteinuria, bioincompatible
membrane, intradialytic hypotension, and dialysis
frequency6570; RKF is inversely correlated with dial-
ysis vintage.68Kidney International Reports (2020) 5, 135–148
M Murea et al.: Hemodialysis in Early-Stage ESKD REVIEWApart from stdKT/Vurea, other methods have been
proposed and are used for evaluation of the equiva-
lency of different schedules of HD, such as weekly urea
reduction ratio, weekly solute removal index, weekly
fractional solute removal, and equivalent renal clear-
ance.62,71 The European guidelines recommend the use
of stdKt/Vurea, EKR, and solute removal index.
72
Because the solute removal index has conflicting defi-
nitions, EKRd, which represents the dialysis equivalent
urea clearance per dialysis session, is used as suggested
by Casino and Lopez.73 Opinion-based clinical practice
guidelines advise to achieve a total EKR (EKRd þ RKF)
at least equal to the adequacy value corresponding to
an equilibrated Kt/Vurea of 1.2 in anuric patients on a
thrice-weekly HD regimen, that is, 12 ml/min per 35
L.17,74 As with other measurements of dialysis dose, the
shortcoming of total EKR is lack of parameter valida-
tion in prospective clinical trials and regimens of in-
cremental HD.75
Several other models have been proposed for pre-
scription of incremental HD. The latest, called the
Variable Target Model (VTM), takes into account the
dynamic changes of Kru and the ability for fine tuning
Kd, thus giving more clinical weight to the contribu-
tion of RKF to the total solute clearance.76 Casino and
Basile showed that once-weekly HD would virtually
not be accomplished under a conventional fixed target
model of urea clearance, but would be accomplished
with VTM for Kru w 5 ml/min per 1.73 m2 (corrected
for end-dialysis urea distribution). Using the VTM,
once-weekly HD was achievable until the corrected Kru
fell to <4 ml/min per 1.73 m2, at which point the
schedule needed to change to twice-weekly HD, which,
in turn, was maintained until the corrected Kru fell
to <2 ml/min per 1.73 m2.76 Although the VTM may
allow for less frequent HD treatments at lower levels of
RKF, limitations of this model are to be acknowledged,
such as the need for high-intensity monitoring and
computation, and lack of prospective studies to test
VTM feasibility at larger scale.
Together, these studies highlight the complexity of
prescribing incremental HD, the large variability in the
practice of less frequent HD, and the irregularity in
obtaining periodic assessments of RKF. For practical
reasons, it can be argued that patients with CKD who
progress to ESKD and have urine output $500 ml/
d (i.e., early-stage ESKD), without a recent abrupt
decline in kidney function (i.e., eGFR <30 ml/min per
1.73 m2 in the 90 days preceding dialysis initiation) will
inherently harbor sufficient RKF to permit prescription
of twice-weekly HD, at least for a limited period. The
concept of time-limited stepped HD will be tested in a
proof-of-concept clinical trial and is discussed below.
The study of a practical HD prescription that considersKidney International Reports (2020) 5, 135–148the progressive nature of CKD and overcomes practice-
based limitations (i.e., assessments of RKF with inter-
dialytic urine collection) is urgently needed.
Potential Advantages of Less Intensive HD
Introduction of HD befalls a vulnerable state and her-
alds high rates of adverse events. Mortality is highest
in the first 6 months of maintenance HD therapy, with
many factors converging to yield 80% higher death
risk in the first 2 months of renal replacement ther-
apy.77,78 Confounding by indication as a result of
clinical deterioration that may prompt the physician to
initiate HD can explain, to a certain extent, the
exceptionally high death rate in the first months of
conventional dialysis. It has also been argued that
abrupt transition from nondialysis-dependent CKD to
thrice-weekly HD could contribute to the high mor-
tality rate.
Indeed, loss of RKF after HD initiation can be a factor
in the high mortality rate.7981 Hemodialysis can cause
episodic ischemic damage to the kidneys, leading to
repetitive bouts of ischemic events that may accelerate
the decline in RKF. It has also been theorized that, with
progressive loss of kidney function, the remaining
functioning nephrons are activated to undergo
compensatory adaptations; initiation of dialysis may
lead to the deactivation of functioning nephrons and
deterioration of RKF.82 Volume expansion is thought to
be a stimulus for the functioning nephrons, and its loss
by dialysis may play a role in RKF decline after dialysis
initiation.83 It has been further speculated that the
diseased kidney’s adaptation might remain stimulated
when dialysis is gently and incrementally introduced, a
concept called “the intact nephron hypothesis in
reverse.”82 Consistent with the hypothesis that HD-
dependent factors contribute to changes in RKF are
the observations that RKF declines more rapidly in
patients on 6-times-per-week nocturnal HD than 3-
times-per-week nocturnal HD, and declines in pa-
tients on in-center thrice-weekly HD more rapidly than
those on PD therapy.68,81 Retrospective and observa-
tional studies showed that a regimen of twice-weekly
HD at dialysis initiation may confer better RKF pres-
ervation than thrice-weekly HD treatment.65,69 The
potential salutary effects of less frequent HD on
intrinsic kidney function can also be gleaned from the
studies that involved patients with dialysis-dependent
acute kidney injury. A post hoc analysis of the Acute
Renal Failure Trial Network study compared the rate of
renal recovery at day 28 between participants ran-
domized to intermittent HD 3 times per week (n ¼ 138)
and 6 times per week (n ¼ 108).84 This study indicated
that patients treated with more frequent HD experi-
enced lower rates of renal function recovery (creatinine141
REVIEW M Murea et al.: Hemodialysis in Early-Stage ESKDclearance >20 ml/min) by day 28 (odds ratio ¼ 0.49,
95% CI ¼ 0.28–0.87).84
The long-standing observations that patients treated
with PD, relative to those treated with HD, have slower
decline of RKF bring additional support to the effect of
dialysis intensity on RKF. Compared to HD, PD is a less
intensive form of renal replacement therapy. In 1
prospective observational study of 50 patients with
incident ESKD divided into 2 groups and matched for
baseline creatinine clearance (4.3  2.4 ml/min) prior to
dialysis initiation, patients in group 1 (n ¼ 25) treated
with continuous ambulatory PD had slower decline of
creatinine clearance over a period of 18 months
compared to those in group 2 treated with intermittent
HD (4.4  2.2 vs. 2.7 ml/min  1.8 at 6 months, 3.8 
1.8 vs. 2.1  1.5 at 12 months, and 4.0  2.3 vs. 1.3 
1.2 at 18 months of dialysis).85 Moreover, a large body
of literature has shown that the level of RKF in patients
treated with PD has a strong correlation with patient
survival, and mathematically equivalent rates of solute
removal with RKF and PD do not render equivalent
patient survival. In 1995, Maiorca et al. reported a 50%
reduction in mortality in patients on PD patients who
had some ongoing kidney function (i.e., glomerular
filtration rate 10 L/wk per 1.73 m2).86 Later, larger
prospective studies reported a strong correlation be-
tween residual renal creatinine clearance and patient
survival, and lack of a similar correlation between
dialysis peritoneal clearance and survival. Diaz-Buxo
et al. observed a doseresponse association between
RKF and outcomes; each increase in renal creatinine
clearance of 5 L/wk per 1.73 m2 was associated with a
10% decrease in mortality, and no association was seen
between peritoneal creatinine clearance and mortal-
ity.87 Subsequent reanalyses of landmark multicenter
clinical trials confirmed that the endogenous clearance
(i.e., RKF) is an essential marker of patient survival,
whereas the exogenous clearance (i.e., dialysis dose
delivered via PD) has much less of an effect on clinical
outcomes.8891
Research on changes in RKF in patients with incident
ESKD treated with HD and the associated effects on
patient outcomes is scant. Patients on HD with higher
levels of RKF have generally reported better quality of
life,81 and longer survival than those with lower levels
of RKF.92 Confounding the results is selection bias,
whereby patients perceived as healthier, more
compliant with treatment recommendations, and with
better kidney function at dialysis initiation are offered
less frequent HD. These very plausible clinical sce-
narios select patients with inherent biological advan-
tage for better clinical outcomes, whereas statistical
methods used in observational studies are unable to
adjust for covert biological factors.142A few retrospective studies have examined survival
in patients with incident ESKD initiated on mainte-
nance dialysis with twice-weekly HD and have re-
ported mixed results. A study done in Lithuania
compared survival between patients initiated on once-
per-week HD (n ¼ 109) and twice-per-week HD (n ¼
747) with patients who began dialysis with 3 sessions
of HD per week (n ¼ 1207), and concluded that HD
frequency of less than 3 times per week was an inde-
pendent risk factor for death after adjustment for age,
sex, and primary kidney disease (relative risk ¼ 1.92,
95% CI ¼ 1.643–2.24, P < .001).93 A larger study
analyzed incident ESKD population from the USRDS,
initiated on HD between 2007 and 2011, including 434
patients treated with less frequent (twice-weekly or
less) HD and 50,162 patients treated with conventional
(thrice-weekly) HD, matched by demographic charac-
teristics (age, sex, race, and central venous catheter as
vascular access) and comorbidity burden. After
adjustment for RKF, all-cause mortality was not
significantly different in the less frequent compared
with conventional HD group (hazard ratio ¼ 0.88, 95%
CI ¼ 0.72–1.08).53 In another retrospective study of
patients initiated on renal replacement with twice-
weekly HD, those who survived longer than 3
months had higher mortality if the they had baseline
Kru #3 ml/min per 1.73 m2, urine volume #600 ml/d,
or interdialytic weight gains $6% of the dry weight;
importantly, follow-up Kru levels were not evaluated
in this study.64 Together, these reports suggest the
possibility that twice-weekly HD, when maintained for
an unchecked duration after dialysis initiation, could
impose negative effects on patient outcomes, likely due
to occult erosion of RKF.
Apart from better preservation of intrinsic kidney
function, other potential advantages of an initial
regimen of less intensive HD (e.g., less frequent or
shorter dialysis) include better patient satisfaction with
health-related quality of life and end-of-life concerns,
while containing costs and resources.94 Some studies,
however, did not find a significant difference in the
overall patient-reported quality of life and depression
screening in patients treated with incremental HD
versus those receiving conventional thrice-weekly
HD.95,96 Two sessions of HD per week upon initiating
dialysis therapy means less frequent cannulations of a
new arteriovenous access, which may prolong fistula or
graft longevity. Vascular accessrelated events (first
event of repair, loss, or access-related hospitalization)
were analyzed in a trial that randomly assigned 245
prevalent dialysis patients to receive in-center 6-times-
per-week HD or HD 3-times-per-week HD and 87 pa-
tients to receive home nocturnal 6-times-per-week HD
or 3-times-per-week HD for 12 months.97 Across allKidney International Reports (2020) 5, 135–148
Table 1. Perceived barriers to incremental hemodialysis
Obstacle Reason Potential solution
Concern for inadequate clearance of uremic solutes
(including solutes other than urea) due to
insidious and unpredictable loss of RKF
No study done to determine the required minimum
amount of solute clearance in patients with incident
ESKD, with or without appreciable RKF, starting HD.
At risk for untimely transition from less frequent to
conventional thrice-weekly HD treatments
Time-delineated incremental HD
Concern for insidious onset of volume overload and
adverse clinical outcomes
In patients on conventional thrice-weekly HD, patient
mortality is higher after the longer interdialytic
interval.
Aggressive combined diuretic therapy
Timely adjustment in target weight and dialysis duration/
frequency
Undefined effects on patient survival and other
important clinical outcomes (e.g., changes in
RKF, rate of cardiovascular events, hospitalization,
nutrition, vascular access complications, quality of
life, control of uremic symptoms)
Retrospective, observational data on incremental HD
produced heterogeneous results.
Clinical trials powered to determine the effects of different
schedules of incremental HD on patient survival
Uncertain patient adherence to serial urine collections Reliance on potentially inaccurate urine collections.
Retrospective studies showed that RKF assessment is
not routinely done, even at dialysis units with
structural organization for incremental HD.
An incentive for patients to collect urine is incremental
dialysis (less frequent and/or shorter HD sessions)
Uncertain patient adherence to recommended
changes in HD treatment frequency or length
Many nephrologists experience patient refusal when
increasing the dialysis frequency/time; this risk has
not been systematically quantified.
Set expectations from the outset: when the time comes to
increase HD dose, the discussion is about how to do it,
not whether it will be done. Leadership and firmness
must accompany the empathy for the added dialysis
burden.98
Faulty identification of patients who can undergo
incremental HD
Assessment of RKF may be inaccurate.
Confusion among nephrologists about the suitable
tests to assess RKF
A large panel of criteria to identify patients suitable for
incremental HD perceived as not pragmatic
Apply incremental HD to cases of certain suitability
Simplify suitability criteria to consist mainly of urine
output volume and patient volume status
Added workload for the dialysis staff and
nephrologist
Requirement of additional medical team members to
monitor serial assessment of RKF and to implement
changes in HD prescription in a timely manner
Operationalize the process of serial urine collections
Develop an automatic electronic system to calculate
RKF, Kru (based on interdialytic urine collection), and
the required dialysis spKt/Vurea (based on HD
prescription) to achieve desired stdKt/Vurea
Shortfall in financial reimbursement for all dialysis
stakeholders
Per current reimbursement model, payment is based
on the number of dialysis sessions delivered per
patient.
Use shorter, thrice-weekly HD as the form of incremental
HD; this approach bears no financial shortfalls, unless
spKt/Vurea reports <1.2.
ESKD, end-stage kidney disease; HD, hemodialysis; RKF, residual kidney function.
M Murea et al.: Hemodialysis in Early-Stage ESKD REVIEWparticipants, frequent HD significantly increased the
risk of vascular access complications (hazard ratio ¼
1.76, 95% CI ¼ 1.11–2.79); in the subgroup of 198 pa-
tients using an arteriovenous fistula or graft at
randomization, there was a similarly increased risk of
vascular accessrelated events with frequent HD (haz-
ard ratio¼ 1.90, 95% CI¼ 1.11–3.25).97 The converse—
namely, that less frequent access cannulationwould lead
to better vascular access outcomes—cannot be inferred,
and at present there is no evidence that twice-weekly
versus thrice-weekly access cannulation has an impact
on vascular access longevity. It can also be conjectured
that buttonhole access cannulation might be safely
applied in patients who undergo once- or twice-weekly
HD; however, access outcomes using this cannulation
technique with less frequent HD are still to be studied.
Potential Disadvantages and Barriers in Prescribing
Less Intensive HD
To achieve widespread scientific recognition and clin-
ical implementation of incremental HD, many obstacles
ought to be overcome. Table 198 summarizes the main
barriers to incremental HD as well as potential solutions,
some of which have been discussed above. It is of utmostKidney International Reports (2020) 5, 135–148importance that patient adherence and survival are
rigorously evaluated in clinical trials before large-scale
implementation of different schedules of HD. Un-
doubtedly, some apprehension in prescribing twice-
weekly HD may stem from the reports of increased
mortality after longer interdialytic intervals, possibly
caused by higher interdialytic weight gains and/or
hyperkalemia.99,100 These data, nevertheless, come from
the analysis of the prevalent dialysis population, most of
whom have little or no RKF. It can be contended that, in
incident patients with early-stage ESKD and RKF,
proper use of pharmacologic measures and timely con-
version from twice-weekly to thrice-weekly HD can
prevent large interdialytic weight gains and severe
hyperkalemia. Indeed, the variability in RKF loss,
coupled with the low success rate of obtaining serial
measurements in RKF, create room for error and un-
certainty in deciding on the timing of transition from a
less frequent to a thrice-weekly HD schedule. In a
cohort of 434 patients with incident ESKD treated with
less frequent incremental HD, 155 patient (36%) tran-
sitioned to conventional HD treatment frequency after a
median of 9 months (interquartile range, 315) of a less
frequent HD treatment schedule (i.e.,<2.5 HD treatment143
Table 2. Summary of randomized pilot trials in the study of less frequent hemodialysis
Principal investigator(s),
study,
N [ planned participant
enrollment (per arm) Intervention arm Comparator arm Key enrollment criteria
Primary
Outcome
Country and
date of
application
Clinical Trial
Registry number
Diera et al.105
Incremental Hemodialysis in Incident
Patients (IHDIP)
N ¼ 75
Once-weekly HD. The number of
HD sessions
per week is increased to 2 and later
to 3 per
criteria for progression.
Thrice-weekly HD  Age $18 yr
 CKD stage 5
 KrU $ 4 ml/min
per 1.73 m2
Patient
survival
Spain,
August 2017
NCT03239808
Fernándex and Teruel106
Incremental Hemodialysis as a
Starting Way of Renal Replacement
Therapy
N ¼ 42
Twice-weekly HD Thrice-weekly HD  Kru $ to 2.5 ml/min
 Urine output: nonanuric
Change
in RKF
Spain,
October 2017
NCT03302546
Vilar107
Incremental HD
N ¼ 25
Twice-weekly HD. The dialysis
dose is adjusted
according to measurement of RKF.
Thrice-weekly HD  Age $18 yr
 HD vintage #3 mo
 Kru $3 ml/min
per 1.73m2
Feasibility United Kingdom,
February 2018
NCT03418181
Murea108
The TWOPLUS-HD Pilot Trial
N ¼ 101
Twice-weekly HD for 6 wk plus
adjuvant
pharmacologic therapy (diuretics,
potassium
binder, sodium bicarbonate)
followed by
thrice-weekly HD.
Thrice-weekly HD  Age $18 yr
 ESKD due to CKD
progression
 HD vintage #7 d
 Urine output $500 ml/d
Feasibility North Carolina, USA,
November 2018
NCT03740048
White109
Dialysis-Less Frequently In The Elderly
(D-LITE)
N ¼ 20
Twice-weekly HD Thrice-weekly HD  Age $70 yr
 Incident ESKD and
survived on HD $7 wk
Feasibility Canada,
December 2018
NCT03787719
Sirich110
Efficacy of Twice Weekly Hemodialysis
in Patients With Residual Kidney
Function
N ¼ 25
Twice-weekly HD for 4 wk,
cross-over design
Thrice-weekly HD
for 4 wk; cross-
over design
 Kru $ 2.5 ml/min Kidney
disease
related QoL
California, USA,
March 2019
NCT03874117
CKD, chronic kidney disease; ESKD, end-stage kidney disease; HD, hemodialysis; Kru, residual renal urea clearance measured by timed urine collection; QoL, quality of life; RKF, residual
kidney function.
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tients with incident ESKD initiated on twice-weekly
HD, time to transition to thrice-weekly HD was highly
variable, after a range of 30 to 1255 days on twice-
weekly HD.54 Virtually all other studies on incremen-
tal in-center HD did not record the point of transition
from less frequent to thrice-weekly HD.64,69,93,94,101,102
There is also some confusion among nephrologists
about the suitable tests to assess RKF: urea clearance,
average urea and creatinine clearance, 24-hour urine
output, or interdialytic urine output. The latest litera-
ture about incremental HD uses urea clearance and
urine output. Concern for lack of patient adherence to
changes in HD frequency and/or length hinders the
practicability of incremental in-center HD. An open HD
regimen of less frequent schedule may generate unre-
alistic expectations to many dialysis patients that less
frequent HD can continue for lengthy periods of time.
This practical limitation may be averted by an initial
implementation of a stepped HD regimen, in which the
boundary of twice-weekly HD is delineated upfront.
A Step Forward
An important feature of the incremental transition to
dialysis is its patient-centeredness that is consistent144with precision medicine in ESKD.103 To this end, there
has been an exponential interest in incremental tran-
sition to dialysis among patient groups who believe
that this is a more gentle and patient-friendly approach
as opposed to the traditional outright 3-times-per-week
HD schedule under the current standard of care. In-
cremental dialysis may become the treatment of choice
under the End-stage renal disease Seamless Care Orga-
nizations (ESCO) as well as under the US government’s
12 July 2019 Executive Order on “Advancing Amer-
ican Kidney Health Initiative” (AAKHI), given that
more home HD therapy means higher utility of incre-
mental dialysis protocols.104
Notwithstanding these developments, the lack of
clinical trialbased evidence in the prescription of HD
initiation means that the clinical safety, clinical effec-
tiveness, and cost-effectiveness of 1 regimen versus
another have not been established; this lack of evidence
highlights the need for robust primary research. We
and other researchers have launched pilot trials as a
first step to moving a new process of HD initiation into
the research arena. Table 2105–110 summarizes the de-
signs of several recently initiated and/or ongoing pilot
trials that study safety and effectiveness of less
frequent HD in patients with incident ESKD, most ofKidney International Reports (2020) 5, 135–148
M Murea et al.: Hemodialysis in Early-Stage ESKD REVIEWwhich consist of twice-weekly HD regimens at dialysis
initiation. Different research designs will shed different
amounts of light on how treatments work under
controlled conditions. To reduce the inherent limita-
tions associated with dependence on frequent mea-
surements of RKF, we are studying the feasibility of a
regimen of stepped HD as a pragmatic alternative of
incremental HD in the TWOPLUS pilot trial
(NCT03740048). With this regimen, patients with
incident ESKD and clinical evidence of satisfactory RKF
(i.e., urine output $500 ml/d) are randomized to either
a dialysis regimen of time-limited twice-weekly in-
center HD schedule and adjuvant pharmacologic ther-
apy (i.e., effective aggressive diuretics, patiromer, and
sodium bicarbonate) for 6 weeks, continued with
thrice-weekly HD, or a standard regimen of thrice-
weekly in-center HD. We believe that a time-
delineated prescription of twice-weekly HD, whether
of 6 weeks or longer, will prevent extension of less
frequent HD schedules into late-stage ESKD when there
is a high risk of unexpected, sudden loss of RKF.
Although the timeframe of 6 weeks for twice-weekly in-
center HD used in the TWOPLUS pilot trial may seem
arbitrary, a conservative approach was elected because
of untested clinical and financial repercussions. To our
knowledge, there has been no study to prospectively
record, in patients with incident ESKD, longitudinal
changes in RKF based on different schedules of HD
frequency. Based on other reports and our experience,
enough RKF to decrease the dialysis burden at HD
initiation may last from 4 to 6 weeks at a minimum to as
much as 4 to 6 years, with an average timeframe of 4 to 12
months.98 Given the intention to apply less frequent in-
center HD on a larger scale in the TWOPLUS trial,
agnostic of eventual fiscal ramifications and patient
compliance with timed urine collections and changes in
HD frequency, we cautiously structured time-
delineated twice-weekly HD by choosing the shorter
duration of time when meaningful RKF would be pre-
sent to allow safe prescription of less frequent HD.
Conclusions
Despite growing evidence of potential benefits of less
frequent HD in early-stage ESKD, changes in HD
practice will require results from randomized trials. To
do less for today’s patients than for the patients of the
past may make clinicians feel exposed. Less frequent
HD might restrict revenue streams. Until more data and
knowledge are accrued, most clinicians will treat CKD
progression to ESKD with long-standing practice con-
ventions. Pending clinical trials, the ideal incremental
HD, which implies that the dose and frequency of
dialysis treatments can be lower at dialysis inception,
in the presence of a substantial RKF, but should beKidney International Reports (2020) 5, 135–148gradually and timely increased to compensate for
subsequent reductions in RKF—determined by inter-
dialytic urine collections—may not be tenable on an
immediate and large scale. A stepped regimen of time-
delineated twice-weekly in-center HD with adjuvant
pharmacologic regimen may set the stage for stream-
lined practice of less frequent HD and obviate the need
for repetitive (and unreliable) urine collections.DISCLOSURE
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